Fluzoparib’s high selectivity for PARP1/2 potently inhibits base excision repair, leading to accumulation of DNA double-strand breaks that cannot be repaired in HRR-deficient tumor cells (Kutuzov et al., 2021). This evidence concerns the gene PARP1 and neoplasm.